What did @gina.nacnac actually say?
The creator, going by the nickname "Tessa" to avoid platform flags, described using tesamorelin, an FDA-approved growth hormone-releasing hormone (GHRH) analogue. She claimed it "reduce[s] the fluff around the mid-section" while also "promoting growth," suggesting it could simultaneously slim the waist and build the glutes. She reported personal results including reduced cellulite and glute growth, but also experienced significant water retention, bloating, and eventually carpal tunnel symptoms she attributed to excess growth hormone stimulation. She openly acknowledged going "gray market" without medical guidance, and offered followers links to both unregulated gray-market sources and a doctor-led compounding pharmacy protocol.
Does the science back this up?
Tesamorelin's fat-reduction effect is real and well-documented, but almost entirely in a specific population. The glute-growth claim has almost no clinical support.
Tesamorelin (brand name Egrifta) received FDA approval in 2010 specifically for HIV-associated lipodystrophy, a condition causing excess visceral abdominal fat. The pivotal trials by Falutz et al. (2010, Journal of Clinical Endocrinology and Metabolism) showed statistically significant reductions in visceral adipose tissue in HIV patients, not healthy adults chasing aesthetics. A 2011 follow-up in the same journal confirmed effects diminished after stopping use.
For healthy individuals without lipodystrophy, the evidence is thin. A 2019 review by Stanley and Grinspoon in Best Practice and Research Clinical Endocrinology and Metabolism noted that GHRH analogues do raise IGF-1 and may modestly shift body composition, but robust trials in healthy populations simply do not exist at scale. The "grow your glutes" framing specifically is not backed by any controlled study. Muscle hypertrophy from GH elevation is a reasonable hypothesis, not a proven outcome in this context.
What did they get wrong (or right)?
Credit where it's due: the water retention and carpal tunnel disclosures are accurate and refreshingly honest for this genre of content.
Water and sodium retention from GH pathway activation is well-established. Lo et al. (2011, Growth Hormone and IGF Research) documented edema and fluid retention as among the most common adverse effects of GHRH therapy. Carpal tunnel syndrome from GH excess is also documented, reported in Bramnert et al. (2003, European Journal of Endocrinology). Her self-diagnosis that the GH stimulation "was really too much" is plausible and consistent with the literature.
What she got wrong is significant though. Tesamorelin is not approved for cosmetic fat reduction or muscle building in healthy people. Framing it as FDA-approved in a way that implies safety and efficacy for aesthetic goals is misleading. The agency approved it for a disease state. That approval does not extend to waist-snatching. She also casually normalized gray-market sourcing while acknowledging she was "raw dogging and guessing," which is a genuinely dangerous thing to broadcast to 10,000 viewers.
What should you actually know?
If you're considering tesamorelin for cosmetic reasons, the honest answer is that the risk-benefit math is not settled for healthy adults, and the regulatory and safety infrastructure around off-label use matters enormously.
Tesamorelin requires subcutaneous injection, stimulates GH release downstream, and raises IGF-1 levels. Long-term IGF-1 elevation is not consequence-free. Epidemiological associations between elevated IGF-1 and certain cancer risks have been noted in observational data, including work by Renehan et al. (2004, Lancet), though causality in the context of short therapeutic use is not established. Still, this is not a supplement with a benign safety ceiling.
Compounded tesamorelin from a licensed pharmacy under physician supervision is a meaningfully different clinical situation than sourcing from gray-market vendors. The creator acknowledged this distinction herself, which is fair. But she presented both options as roughly equivalent paths, and they are not. Compounding pharmacies regulated under 503A or 503B standards have quality controls. Unregulated gray-market peptide vendors do not, and independent testing of peptide products has repeatedly found dosing inaccuracies and contamination issues.
- Tesamorelin is only FDA-approved for HIV-associated lipodystrophy, not cosmetic use.
- Water retention and carpal tunnel are real, documented side effects, not rare edge cases.
- Gray-market sourcing introduces compound purity and dosing risks with no regulatory backstop.
- The glute growth claim is anecdotal with no controlled trial support in healthy adults.